title: The classification of cyclooxygenase inhibitors.
abstract: In summary, precise classification of COX inhibitors has important clinical implications for efficacy and toxicity. However, classification of these agents clinically is difficult because there are insufficient data to predict correlations between biochemical and pharmacologic properties and the clinical effect of a given agent. In any case, specific COX-2 inhibitors are expected to show antiinflammatory and analgesic activities equivalent to those of NSAID, as well as significant reductions in the incidence of the life threatening side effects (i.e., GI bleeding) associated with COX-1 inhibition. The advantages of preferential COX-2 inhibitors may be more subtle and therefore more difficult to verify in clinical trials.
authors.forename: L P
authors.initials: LP
authors.lastname: Lipsky
authors.forename: S B
authors.initials: SB
authors.lastname: Abramson
authors.forename: L
authors.initials: L
authors.lastname: Crofford
authors.forename: R N
authors.initials: RN
authors.lastname: Dubois
authors.forename: L S
authors.initials: LS
authors.lastname: Simon
authors.forename: L B
authors.initials: LB
authors.lastname: van de Putte
mesh_terms: D000818:Animals; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000145:classification* / Q000494:pharmacology; D006801:Humans; D007527:Isoenzymes / Q000187:drug effects; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases